Question explored with the scientific record
Summarise the evidence that support the Lp(a)hypothesis and critically evaluate their scientific validity
The Lp(a) hypothesis is supported by a strong chain of genetic, epidemiological, and mechanistic evidence, but the critical test—showing that lowering Lp(a) reduces disease—is still unproven.
The core of the Lp(a) hypothesis is that this lipoprotein, which is mostly determined by your genes, directly causes heart disease and aortic valve stenosis. The evidence for this is unusually robust. Large studies like the Copenhagen City Heart Study found that people with Lp(a) above 120 mg/dL had about a 3.6-fold higher risk of myocardial infarction [4]. A massive autopsy study of over 1,000 cases showed that high Lp(a) levels more than tripled the odds of severe coronary stenosis [1]. These are not small effects.
The strongest evidence comes from genetics. Specific variants in the LPA gene that raise Lp(a) levels are consistently linked to a higher risk of heart attack and aortic valve calcification [2, 6]. This is called Mendelian randomization, and it avoids the problem of reverse causation (where the disease changes the Lp(a) level). A 2025 review of this evidence concluded that Lp(a) is a "genetically determined, causal risk factor" [4]. The mechanism is also plausible: Lp(a) carries oxidized phospholipids that drive inflammation and calcification in artery and valve walls [3].
However, the hypothesis has a critical gap. The ultimate proof would be a trial where lowering Lp(a) clearly reduces heart attacks and deaths. That trial has not been done. A 2016 Phase I trial of an antisense drug that lowered Lp(a) by up to 78% was too small and short to measure clinical outcomes [5]. The 2025 review itself notes that the benefits of Lp(a)-lowering therapies are "not yet proven" [4]. This is the same pattern seen with HDL cholesterol: strong genetic and observational evidence that turned out to be misleading when intervention trials failed.
My call: the evidence that Lp(a) is a causal risk factor for cardiovascular disease is strong and scientifically valid. The evidence that lowering it will save lives is absent. Confidence: moderate.
Sources used 6
-
High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases
This study investigates the relationship between high lipoprotein(a) levels and the promotion of coronary atherosclerosis and myocardial infarction through a path analysis of 1062 autopsy cases, revealing that elevated Lp(a) levels significantly increase the risk of severe coron…
DOI: 10.1136/hrt.2008.160879 -
Association of Polymorphisms of the Apolipoprotein(a) Gene With Lipoprotein(a) Levels and Myocardial Infarction
This study investigates the association of polymorphisms in the apolipoprotein(a) gene with lipoprotein(a) levels and the risk of myocardial infarction, revealing that specific haplotypes are linked to increased MI risk, particularly in women.
DOI: 10.1161/01.cir.0000048125.79640.77 -
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
This study investigates the association between elevated lipoprotein(a) and oxidized phospholipids with the progression of calcific aortic valve stenosis, finding that higher levels correlate with faster disease progression and increased need for aortic valve replacement.
DOI: 10.1016/j.jacc.2015.07.020 -
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease
Lipoprotein(a) is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis, with epidemiologic, genetic, and MR data showing risk rises with higher Lp(a) and suggesting potential, though not yet proven, benefits f…
DOI: 10.1007/s12170-025-00760-1 -
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
This review summarizes antisense inhibition of apolipoprotein(a) (apo(a)) as a strategy to lower lipoprotein(a) [Lp(a)] in humans, detailing preclinical proof-of-concept in apo(a) transgenic mice and cynomolgus monkeys and a Phase I trial of the apo(a)-targeted antisense drug IS…
DOI: 10.1194/jlr.R052258 -
Genetic Associations with Valvular Calcification and Aortic Stenosis
This study identifies genetic associations between single nucleotide polymorphisms (SNPs) in the LPA locus and valvular calcification, particularly aortic-valve calcification, across multiple ethnic groups, suggesting a causal role for lipoprotein(a) in the development of aortic…
DOI: 10.1056/NEJMoa1109034